Table 1.
Synopsis of the synergistic action of nanoparticle and siRNA for tumor regression via immune cell activation.
| Nanoparticle type used in synergy with siRNA | Targeted immune Cell |
In-vivo | In-vitro | Gene targeted by siRNA | Comments | Reference |
|---|---|---|---|---|---|---|
| PGLA-based | Dendritic Cells | Lymphoma mice | STAT3; Silencing |
Ovalbumin-specific T-cell activity was observed when NP was administered to lymphoma mice. Growth of tumor restricted. | 68 | |
| Dendritic Cells | B16F10 | STAT3; Silencing |
CD86 expression upregulated, Increased release of TNF-α, Proliferation of allogenic T-cells |
123 | ||
| Dendritic Cells | CD8 OVA 1.3 T cells | SOCS1 | Increased levels of TNF-a, IL-6, IL-12, IL-2, More immunotherapeutic effects |
68 | ||
| PEI-based | Dendritic Cells | Lymphoma mice | B16 melanoma | STAT3; Silencing |
Dendritic cells are enabled to perform CTL activity, Reduced growth of tumor in B16 mice. |
122 |
| Dendritic Cells | Ovarian cancer mice | HEK293 cells | PD-L1; Silencing |
Induction of TLR5 and TLR7, Restoration of the function of Dendritic cells in ovarian cancer mice. |
59 | |
| Dendritic Cells | Ovarian cancer mice | miR-155 | Increased miR-155 activity, Anti-inflammatory mediators silenced, Restoration of CTL activity of Dendritic cells in ovarian cancer mice. |
124 | ||
| Lipid-based | Dendritic Cells | Hep3b cell line | PD-L1 PD-L2; Knockdown |
Knockdown of PD-L expression | 120 | |
| Monocytes | Lymphoma graft | CCR2; Silencing |
No deposition of CCR2 in sites of inflammation, Decrease in tumor volume |
119 | ||
| Lipid Envelope-based | Dendritic Cells | Cell line from Female C57BL/6 (H-2b) mice | A20; Silencing |
LPS stimulation, Increase in immunostimulatory cytokines |
121 | |
| Stearylatedoctaargininelipid-based | Dendritic Cells | HeLa cells and E.G.,7-OVA cells | SOCS1; Silencing |
Increased STAT1 phosphorylation, Increase in immunostimulatory cytokines |
111 | |
| Gold nanoparticles | Macrophages | Lung cancer mice | Mouse BALB/c macrophage J774.2 cell line | VEGF; Silencing |
Decrease in TAMs in lung tumor tissues, Decrease in tumor size, Enhancement of survival in mice |
107 |
| Mannosylated Polymeric Micelles | Macrophages | Breast cancer cell line | CD206; Knockdown |
Improved delivery of the siRNAs, 90% knockdown |
114 |